Asgard Therapeutics
Lund
About Asgard Therapeutics
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $39.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2024)
- Website: asgardthx.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/asgard-therapeutics-35550 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.